Open AccessLessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
Author(s) -
Fiona Chautant,
Maéva Guillaume,
MarieAngèle Robic,
JeanFrançois Cadranel,
JeanMarie Péron,
Hortensia Lison,
Charlène Cool,
Christophe Bureau,
Véronique Duhalde
Publication year - 2020
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v12.i1.10
Subject(s) - rifaximin , medicine , hepatic encephalopathy , lactulose , cirrhosis , retrospective cohort study , clinical endpoint , gastroenterology , intensive care medicine , randomized controlled trial , antibiotics , microbiology and biotechnology , biology
Hepatic encephalopathy (HE) is a major complication of cirrhosis with independent prognostic significance. The current management of HE is mainly based on lactulose. Rifaximin has been shown to decrease the risk of HE recurrence in patients with episodic forms. HE can also be persistent. However, there is no drug support recommendation for rifaximin use in this setting.